DIRS.INFO The most relevant business & tech news

☆ AstraZeneca's COVID vaccine suffers a setback in nasal spray trial
▼ + stars: | 2022-10-10 | by ( ) www.reuters.com time to read: +2 min

Also, the immune response measured in the blood was weaker than that from a shot-in-the-arm vaccination. India's health minister last month approved Bharat Biotech's COVID-19 nasal spray vaccine while China's CanSino Biologics Inc (6185.HK) last month won emergency approval by the country's drug regulator for an inhaled version of its COVID-19 vaccine. The British trial enrolled 30 previously unvaccinated participants as well as 12 volunteers, who had previously received a standard two-dose vaccine course by injection. "The nasal spray did not perform as well in this study as we had hoped," said Sandy Douglas, chief investigator of the trial at Oxford University's Jenner Institute. No serious adverse events or safety concerns were reported during the trial, which was funded by AstraZeneca, according to the statement.

☆ GSK picks Burberry's Brown as CFO
▼ + stars: | 2022-09-26 | by ( ) www.reuters.com time to read: +2 min

Register now for FREE unlimited access to Reuters.com RegisterGSK (GlaxoSmithKline) logo is seen in this illustration, August 10, 2022. REUTERS/Dado Ruvic/Illustration/SummarySummary Companies Brown to join GSK in April, start as CFO in MayCFO Iain Mackay to retireSept 26 (Reuters) - GSK (GSK.L) named luxury fashion brand Burberry's (BRBY.L) Julie Brown as its new chief financial officer on Monday to succeed Iain Mackay, at a time when the British drugmaker is sharpening focus on its core business. The change comes after GSK spun off its large consumer business, Haleon (HLN.L), to focus on prescription drugs and vaccines. Burberry had said on Friday that Brown would step down as its CFO and chief operating officer in April to take up a role outside the luxury industry. Register now for FREE unlimited access to Reuters.com RegisterReporting by Amna Karimi and Pushkala Aripaka in Bengaluru; Editing by Subhranshu Sahu and Louise HeavensOur Standards: The Thomson Reuters Trust Principles.

Mackay, 60, will be retiring next year after serving as GSK's finance chief for nearly four years, following an eight-year stint as group finance director at the bank HSBC. Register now for FREE unlimited access to Reuters.com RegisterBrown, also 60, will join GSK in April and take up the job in May. She also served in several finance roles at AstraZeneca (AZN.L), which last year also appointed a female CFO, Aradhana Sarin. With Emma Walmsley as GSK's chief executive officer, Brown's appointment also creates a rare, all-female top management at a blue-chip (.FTSE) British company and a global pharma major. Brown will receive an annual base salary of more than 900,000 pounds at GSK, the company said.

Register now for FREE unlimited access to Reuters.com RegisterGSK (GlaxoSmithKline) logo is seen in this illustration, August 10, 2022. REUTERS/Dado Ruvic/Illustration/SummarySummary Companies Brown to join GSK in AprilIain Mackay to retire in MaySept 26 (Reuters) - Britain's GSK (GSK.L) has appointed its first female chief financial officer, Julie Brown, to succeed Iain Mackay, as the drugmaker focuses on its core pharmaceuticals business. With Emma Walmsley as GSK's chief executive, Brown's appointment also creates a rare, all-female top management at a blue-chip (.FTSE) British company and a global pharma major. Mackay, 60, will retire next year after almost four years as GSK's finance chief, before which he completed an eight-year stint as group finance director at HSBC. She also served in several finance roles at AstraZeneca (AZN.L), which last year appointed a female CFO, Aradhana Sarin.

Search resuls for: "AZN"

4 mentions found